Best in Biotech 2 May 2024 Eight monoclonal antibody biotechs making strides in the clinic …is a monoclonal antibody that works by binding to TIGIT, which could activate the immune system to attack cancer cells. Typically, a fragment crystallizable (Fc) region in a monoclonal antibody,… May 2, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Jul 2025 14 biotech companies to know in the Boston area in 2025 …antibody-based therapies that reprogram the tumor microenvironment to improve the immune system’s ability to fight cancer. Its lead candidate, PRTH‑101, is a monoclonal antibody that targets DDR1, a collagen-binding receptor… July 4, 2025 - 15 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 8 Aug 2022 Genmab and BioNTech expand collaboration to develop and commercialize immunotherapy candidates …jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint development of bispecific cancer antibodies… August 8, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 26 Aug 2025 Five biotech companies in South Korea you should know about …bind to targets. The most advanced antibody in IMBiologics’ roster is IMB-101, which hit the clinic two months ago. It is a bispecific antibody targeting OX40L and TNF, which modulates both… August 26, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Oxford BioTherapeutics enters into antibody agreement with Genmab …conjugate (ADC) based therapies designed to fulfill major unmet patient needs in cancer therapeutics. These include bispecific, chimeric antigen receptor T-cell (CAR-T), Antibody Drug Conjugate (ADC) and Antibody Dependent Cell-mediated… October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 2 Jul 2024 Swiss biotech going strong in 2024: 18 companies to put on your radar …as a monotherapy and in combination with pembrolizumab, an anti-PD-1 antibody. The company’s most advanced program is Lixudebart (ALE.F02). It is a monoclonal antibody designed to treat organ fibrosis and… July 2, 2024 - 20 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Weekly Roundup 15 Dec 2023 Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered …Squibb to collaborate to develop cancer treatment Antibody therapy company SystImmune is collaborating with Bristol Myers Squibb (BMS) to develop and commercialize BL-B01D1, a bispecific antibody-drug conjugate (ADC). The candidate… December 15, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Feb 2020 Meet 20 European Immuno-Oncology Companies that are Fighting Cancer …very few European biotechs valued at over €1B. MorphoSys develops antibody therapies for numerous conditions. The company’s lead immuno-oncology candidate tafasitamab is a humanized monoclonal antibody that targets CD19, an… February 24, 2020 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Feb 2024 Fourteen biotech companies spearheading the antibody drug conjugate industry …addition to ADRX-0706, Adcentrx is working on a second candidate in oncology indications and another candidate aimed at treating conditions in immunology. The company also entered a three-year partnership with… February 8, 2024 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Sep 2025 Navigating German biotech: 14 key players to know …and the space is competitive, but it’s worth keeping an eye on the Evotec spin-off. CatalYm Founded: 2016 Technology: Anti-GDF-15 monoclonal antibody Lead candidate: Visugromab CatalYm, a spin-out from Würzburg… September 23, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Apr 2025 13 anti-aging startups on a mission to extend lives …becomes a patient. Each candidate in Cambrian’s pipeline targets a different type of damage that builds up with age, spanning obesity, respiratory, oncology, and immunology indications. These candidates are being… April 8, 2025 - 19 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Feb 2025 Eight respiratory disease companies advancing innovative therapies in 2025 …round Endeavor BioMedicines currently has two candidates in its pipeline, one of which is intended for the treatment of fibrotic lung disease. This is the company’s lead candidate, called ENV-101…. February 27, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email